A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer ; volume:18 ; number:3 ; day:21 ; month:4 ; year:2023 ; pages:441-450 ; date:5.2023
Targeted oncology ; 18, Heft 3 (21.4.2023), 441-450, 5.2023

Creator
Heine, Rob ter
Heuvel, Michel M. van den
Piet, Berber
Deenen, Maarten J.
Wekken, Anthonie J. van der
Hendriks, Lizza E. L.
Croes, Sander
Geel, Robin M. J. M. van
Jansman, Frank G. A.
Boshuizen, Rogier C.
Franssen, Eric J. F.
Smit, Arthur A. J.
Dumoulin, Daphne W.
Oude Munnink, Thijs H.
Smit, Egbert F.
Derijks, Hieronymus J.
Leest, Cor H. van der
Hendrikx, Jeroen J. M. A.
Moes, Dirk J. A. R.
Rouw, Nikki de
Contributor
SpringerLink (Online service)

DOI
10.1007/s11523-023-00958-6
URN
urn:nbn:de:101:1-2023090909555163292009
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Heine, Rob ter
  • Heuvel, Michel M. van den
  • Piet, Berber
  • Deenen, Maarten J.
  • Wekken, Anthonie J. van der
  • Hendriks, Lizza E. L.
  • Croes, Sander
  • Geel, Robin M. J. M. van
  • Jansman, Frank G. A.
  • Boshuizen, Rogier C.
  • Franssen, Eric J. F.
  • Smit, Arthur A. J.
  • Dumoulin, Daphne W.
  • Oude Munnink, Thijs H.
  • Smit, Egbert F.
  • Derijks, Hieronymus J.
  • Leest, Cor H. van der
  • Hendrikx, Jeroen J. M. A.
  • Moes, Dirk J. A. R.
  • Rouw, Nikki de
  • SpringerLink (Online service)

Other Objects (12)

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Potential of antibody–drug conjugates (ADCs) for cancer therapy

Potential of antibody–drug conjugates (ADCs) for cancer therapy

Antibody–drug conjugates in ovarian cancer

Antibody–drug conjugates in ovarian cancer

Antibody–drug conjugates—the magic bullet?

Antibody–drug conjugates—the magic bullet?

Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates

Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates

Fate of Antibody-Drug Conjugates in Cancer Cells

Fate of Antibody-Drug Conjugates in Cancer Cells

Antibody–drug conjugates (ADCs) in lung cancer treatment

Antibody–drug conjugates (ADCs) in lung cancer treatment

Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates

Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates

Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review

Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia

Related objects